# SYBX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SYBX) · [Earnings tab](https://www.lopjlb.com/stock/SYBX?tab=earnings)

Updated: 2026-08-10T05:40:19

Quarters analyzed: 8

## Cross-quarter narrative

From late 2020 through early 2022, Synlogic transitioned from early-stage clinical execution across three programs to a focused metabolic pipeline with two lead PKU candidates and extended cash runway. The company demonstrated proof-of-mechanism for SYNB1618 (PKU) and SYNB8802 (enteric hyperoxaluria) in 2020-2021, added next-generation strain SYNB1934 and IND candidate SYNB1353, and secured a Roche IBD research collaboration. Manufacturing capacity was expanded 50% and cash reserves grew from $102M (runway into 2022) to $136.6M (runway into 2024) via equity offerings. However, clinical timelines slipped: SYNB1891 was halted, PKU Phase II data moved to H2 2022 and Phase III to H1 2023 due to site labor shortages, and COVID-19 delta variant initially pressured trial enrollment. Leadership risk emerged with a CMO search. The strategy shifted toward core metabolic programs, discontinuing oncology asset SYNB1891. Regulatory alignment for pediatric PKU, market adoption despite existing therapies, and reliance on niche indications remain persistent uncertainties. The Roche IBD collaboration was delivered, but future partnership visibility is limited. Overall, the pipeline advanced technically while operational risks evolved from pandemic disruption to site-level

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2022 Q2:** —
- **2022 Q1:** Synlogic updates PKU timelines due to site labor shortages (Phase II data H2'22, Phase III H1'23), advances HCU and hyperoxaluria programs, cash runway into 2024.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights significant progress across pipeline, large PKU market opportunity, regul
- **2021 Q4:** Synlogic reports Q4 2021 results, advances PKU lead program toward Phase III in H2 2022 with two candidates (SYNB1618, SYNB1934), $136.6M cash into 2024, and progresses HCU and enteric hyperoxaluria programs.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize dramatic progress, pro
- **2021 Q3:** Synlogic reported robust PKU data with SYNB1618, added SYNB1934 to its program, and outlined continued focus on metabolic targets while pausing SYNB1891.
- **2021 Q2:** Synlogic Q2 2021 call highlighted proof‑of‑mechanism in PKU and Enteric Hyperoxaluria, launched a Phase 1 for next‑gen PKU strain SYNB1934, advanced SYNB8802 Phase 1B, announced a Roche IBD partnership and a CMO search while monitoring COVID‑19 impacts.
- **2021 Q1:** Synlogic Q1 2021: proof of mechanism for SYNB1618 (PKU) and SYNB8802 (enteric hyperoxaluria); proof-of-concept readouts H2 2021; manufacturing expansion 50%; cash runway to H2 2023 after $32.6M offering.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management expresses confidence in execution, proof of
- **2020 Q4:** Synlogic reports Q4 2020 results, highlights SYNB8802 proof-of-mechanism in Enteric Hyperoxaluria with 28.6% urinary oxalate reduction, advancing to Phase 1b in patients; SYNB1618 Phase 2 enrolling well; cash runway into 2023.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize exci
- **2020 Q3:** Synlogic reports Q3 2020 results with $102M cash (runway into 2022), advances three clinical programs: SYNB1618 Phase 2 PKU initiated, SYNB8802 Phase 1 enteric hyperoxaluria started early, SYNB1891 Phase 1 monotherapy ongoing with interim data expected year-end. New CSO hired, IBD asset returned fro

## Guidance path

2020 Q3:vague → 2020 Q4:vague → 2021 Q1:vague → 2021 Q2:maintained → 2021 Q3:vague → 2021 Q4:vague → 2022 Q1:vague → 2022 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SYBX`